Patient-reported outcomes measures in generalized myasthenia gravis (gMG) are more important than ever, for both those ...

Cabaletta has been evaluating the CAR-T, called resecabtagene autoleucel or rese-cel , across six so-called RESET studies ...

These are data to week 26 on the monoclonal antibody and antineoplastic agent; data out to week 52 of the MINT trial will be ...

More than 500 members of the myasthenia gravis (MG) rare disease community will come together this week in-person and ...

Sunshine Cruz recently revealed that she’s battling an autoimmune disease called myasthenia gravis. In an Instagram post, the ...

Sunshine Cruz shared that she has been diagnosed with an autoimmune disease, just a few days after walking in the Bench Body ...

Interim data from phase 2 KYSA-6 study, using KYV-101 for the treatment of patients with Myasthenia Gravis, expected 2nd half ...

Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T entering Phase 3 ...

Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the ...